15 results on '"Valentina Kiren"'
Search Results
2. Improving Drug Safety in Pediatric and Young Adult Patients with Hemato-Oncological Diseases: A Prospective Study of Active Pharmacovigilance
- Author
-
Anna Parzianello, Giulia Fornasier, Valentina Kiren, Federico Pigato, Sabrina Orzetti, Giulia Zamagni, Anna Arbo, Paolo Baldo, Paola Rossi, Marco Rabusin, Maurizio Mascarin, and Marta Paulina Trojniak
- Subjects
pharmacovigilance ,adverse drug reaction ,hemato-oncological disease ,pediatric population ,safety ,multidisciplinary team ,Medicine ,Pharmacy and materia medica ,RS1-441 - Abstract
The acquisition of relevant pediatric clinical safety data is essential to ensure tolerable drug therapies. Comparing the real number of Adverse Drug Reaction (ADR) reports in clinical practice with the literature, the idea of ADR underreporting emerges. An active pharmacovigilance observational prospective study was conducted to assess the safety of oncology pharmacological prescriptions in patients aged 0–24 years at Institute for Maternal and Child Health IRCCS Burlo Garofolo in Trieste and IRCCS CRO National Cancer Institute in Aviano (Italy) between January 2021 and October 2023. Prescriptions and ADRs were evaluated by a multidisciplinary team. A total of 1218 prescriptions for 38 patients were analyzed, and 190 ADRs of grade 3–5 were collected. As compared to historical data, we registered a significant increase (p < 0.001) in the number of ADRs. The risk of ADR was 3.4 times higher in the case of off-label prescriptions compared to on-label ones (OR 3.4; [1.47; 7.89]; p-value = 0.004). The risks of error and near-miss were reported for 6.3% and 18.2% of total prescriptions, respectively. Of the total of 133 interactions, 47 (35.3%) resulted in ADRs. This study shows the importance of pro-active pharmacovigilance to efficiently highlight ADRs, and the fundamental role of multidisciplinary teams (oncologist, pharmacist, pharmacologist, pediatrician, nurse) in improving patients’ safety during therapy.
- Published
- 2024
- Full Text
- View/download PDF
3. Case report: Venetoclax therapy in a boy with acute myeloid leukemia in Shwachman Diamond syndrome
- Author
-
Samuele Naviglio, Antonio Giacomo Grasso, Chiara Iacono, Giada Zanella, Valentina Kiren, Nagua Giurici, Federico Verzegnassi, Natalia Maximova, and Marco Rabusin
- Subjects
Shwachman Diamond syndrome ,venetoclax ,acute myeloid leukemia ,myelodysplastic syndromes ,pediatric ,Pediatrics ,RJ1-570 - Abstract
Shwachman-Diamond syndrome (SDS) is a rare bone marrow failure syndrome characterized by exocrine pancreatic insufficiency, bone abnormalities, progressive cytopenia, and predispositions to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). AML, in these patients, is associated with a poor prognosis and with an increased risk of organ toxicity and infectious complications from chemotherapy and hematopoietic stem cell transplantation (HSCT), thus leading to high rates of treatment-related morbidity and mortality. The BCL-2 inhibitor venetoclax has revolutionized the treatment of AML in elderly adults, especially for treatment-naive elderly patients who are ineligible for intensive chemotherapy. There is limited evidence on the use of venetoclax in pediatric patients with SDS-related MDS or AML. Here, we report a case of a 14-year-old boy with SDS with AML arising from MDS. The patient was treated with two cycles of conventional chemotherapy with fludarabine and cytarabine with an initial good response but immediate relapse and substantial toxicity. Treatment with venetoclax and azacitidine was started, with a substantial reduction of leukemic burden (good response on peripheral leukemic infiltration and partial response in the bone marrow after one course). However, it was followed by multiple infectious complications and worsening of the general condition not allowing treatment to be continued, and the patient eventually died from multiorgan failure. With the limitations of observation of a single patient, our experience suggests that venetoclax/azacitidine combination therapy may represent a therapeutic possibility for patients with SDS and AML, even though it may be associated with significant toxicity.
- Published
- 2023
- Full Text
- View/download PDF
4. Case Report: Use of Anakinra in Multisystem Inflammatory Syndrome During COVID-19 Pandemic
- Author
-
Sara Della Paolera, Erica Valencic, Elisa Piscianz, Valentina Moressa, Alberto Tommasini, Raffaella Sagredini, Valentina Kiren, Manola Comar, and Andrea Taddio
- Subjects
MISC-C ,PIMS-TS ,COVID-19 ,SARS-CoV-2 ,Kawasaki ,anakinra ,Pediatrics ,RJ1-570 - Abstract
During COVID-19 outbreak, a large number of children with severe inflammatory disease has been reported. This condition, named Pediatric Multi-inflammatory Syndrome temporally associated with COVID-19 (PIMS-TS) or Multisystem Inflammatory Syndrome associated with Coronavirus Disease 2019 (MIS-C), shares some clinical features with Kawasaki disease and is frequently complicated by myocarditis or shock. It has been suggested that MIS-C belongs to the group of cytokine storm syndromes triggered by SARS-CoV-2 infection. So far, intravenous immunoglobulin (IVIG) and systemic glucocorticoids are the most common therapeutic approaches reported in this group of patients. However, the use of anakinra in patients with severe forms of COVID-19 is showing promising results. Here we reported two patients with multisystem inflammatory syndrome complicated with shock. Both the patients presented a poor response to IVIG and systemic glucocorticoids and received anakinra. Treatment with IL-1 receptor antagonist showed a rapid improvement of clinical conditions and biochemical analysis in both patients and demonstrated a good safety profile. Thus, we look forward for future controlled clinical trials with the aim to demonstrate the effectiveness of anakinra in patients with MIS-C and established precise criteria for its use.
- Published
- 2021
- Full Text
- View/download PDF
5. Marriage and parenthood among childhood cancer survivors: a report from the Italian AIEOP Off-Therapy Registry
- Author
-
Emanuele Pivetta, Milena M. Maule, Paola Pisani, Daniela Zugna, Riccardo Haupt, Momcilo Jankovic, Maurizio Aricò, Fiorina Casale, Anna Clerico, Luca Cordero di Montezemolo, Valentina Kiren, Franco Locatelli, Giovanna Palumbo, Andrea Pession, Marta Pillon, Nicola Santoro, Monica Terenziani, Maria Grazia Valsecchi, Elisa Dama, Corrado Magnani, Franco Merletti, and Guido Pastore
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Background The aim of this study was to describe the patterns of marriage and parenthood in a cohort of childhood cancer survivors included in the Off-Therapy Registry maintained by the Italian Association of Pediatric Hematology and Oncology.Design and Methods We analyzed a cohort of 6,044 patients diagnosed with cancer between 1960 and 1998, while aged 0 to 14 years and who were 18 years old or older by December 2003. They were followed up through the regional vital statistics registers until death or the end of follow up (October 30, 2006), whichever occurred first, and their marital status and date of birth of their children were recorded. The cumulative probabilities of being married and having a first child were computed by gender and compared by tumor type within the cohort. Marriage and fertility rates (the latter defined as the number of live births per woman-year) were compared with those of the Italian population of the same age, gender, area of residence and calendar period by means of the observed to expected (O/E) ratios.Results During the follow-up period, 4,633 (77%) subjects had not married. The marriage O/E ratios were 0.56 (95% CI: 0.51–0.61) and 0.70 (95% CI: 0.65–0.76) among men and women, respectively. Overall, 263 men had 367 liveborn children, and 473 women had 697 liveborn children. The female fertility O/E ratio was 0.57 (95% CI: 0.53–0.62) overall, and 1.08 (95% CI: 0.99–1.17) when analyses were restricted to married/cohabiting womenConclusions Childhood cancer survivors are less likely to marry and to have children than the general population, confirming the life-long impact of their previous disease on their social behavior and choices. The inclusion of counseling in the strategies of management and long-term surveillance of childhood cancer patients could be beneficial to survivors as they approach adulthood.
- Published
- 2011
- Full Text
- View/download PDF
6. Sclerosi tuberosa ed everolimus: una nuova storia
- Author
-
Marco Carrozzi, Valentina Kiren, Giulia Maria Di Marzio, Elisabetta Cattaruzzi, Paola Costa, and Chiara Cervesi
- Subjects
business.industry ,Pediatrics, Perinatology and Child Health ,Medicine ,business - Abstract
Tuberous sclerosis complex (TSC) is a rare autosomal dominant disorder, due to inactivating muta-tions of TSC1 or TSC2 mTOR pathway genes and is characterized by variable multisystem manifestations ranging from hamartomas to malignant neoplasms. It frequently associated to seizures, intellectual disability and behavioural disorders. Surgical treatment has traditionally been used to manage subependymal giant cells astrocytomas (SEGA). The introduction of mTOR inhibitor rapamycin, with its definite role both as primary and as adjuvant treatment, has significantly modified the management opportunities in the clinical practice. It is important to consider both treatment options in a balanced way and not only the SEGA, but also the individual patient and their associated comorbidities. The pros and the cons of both options should be discussed by a multidisciplinary team before establishing an individualized treatment recommendation. The paper reports the case of a patient with an asymptomatic SEGA who was treated with everolimus. The treatment was effective in reducing the size of the tumour, it was safe and well tolerated.
- Published
- 2021
- Full Text
- View/download PDF
7. IL-1 blockade with anakinra for severe inflammatory symptoms during chemotherapy for acute lymphoblastic leukemia
- Author
-
Maria Luisa Coniglio, Samuele Naviglio, Marco Rabusin, Alberto Tommasini, Elena Sieni, Erica Valencic, Valentina Kiren, Federico Verzegnassi, Nagua Giurici, Giada Zanella, Naviglio, S., Zanella, G., Verzegnassi, F., Kiren, V., Giurici, N., Sieni, E., Coniglio, M. L., Valencic, E., Tommasini, A., and Rabusin, M.
- Subjects
Oncology ,Anakinra ,medicine.medical_specialty ,Chemotherapy ,business.industry ,Il-1 ,Lymphoblastic Leukemia ,medicine.medical_treatment ,Hematology ,acute lymphoblastic leukemia ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Blockade ,Interleukin 1 Receptor Antagonist Protein ,Internal medicine ,Pediatrics, Perinatology and Child Health ,Acute Disease ,medicine ,Humans ,business ,medicine.drug ,Interleukin-1 - Abstract
Anakinra is a recombinant interleukin (IL)-1 receptor antagonistusedforseveralinflammatoryconditionsincludingsystemicjuvenileidiopathicarthritis,recurrentpericarditis,andfamilialMediterraneanfever (FMF). Its efficacy in blocking IL-1 and its manageable safetyprofilesupportitsusealsoinotherconditions,suchassepsis,acutemyocardialinfarction,andCOVID-19
- Published
- 2022
- Full Text
- View/download PDF
8. Whole Lung Irradiation after High-Dose Busulfan/Melphalan in Ewing Sarcoma with Lung Metastases: An Italian Sarcoma Group and Associazione Italiana Ematologia Oncologia Pediatrica Joint Study
- Author
-
Massimo Eraldo Abate, Lorenza Gandola, Barbara Diletto, Elisa Coassin, Giovanni Grignani, Carla Manzitti, Valentina Kiren, Arcangelo Prete, Stefano Ferrari, Giuseppe Milano, Nadia Puma, Silvia Cammelli, Alessandra Longhi, Luca Coccoli, Angela Tamburini, Letizia Ronchi, Emanuela Palmerini, Franca Fagioli, Mariella Capasso, Elisa Carretta, Maurizio Mascarin, Anna Paioli, Sebastian Dorin Asaftei, Roberto Luksch, Piero Picci, Marta Pierobon, Gianni Bisogno, Abate M.E., Cammelli S., Ronchi L., Diletto B., Gandola L., Paioli A., Longhi A., Palmerini E., Puma N., Tamburini A., Mascarin M., Coassin E., Prete A., Asaftei S.D., Manzitti C., Bisogno G., Pierobon M., Coccoli L., Capasso M., Grignani G., Milano G.M., Kiren V., Fagioli F., Ferrari S., Picci P., Carretta E., and Luksch R.
- Subjects
0301 basic medicine ,Oncology ,Melphalan ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Article ,03 medical and health sciences ,0302 clinical medicine ,Autologous stem-cell transplantation ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Busulfan ,Ewing sarcoma ,Lung irradiation ,Pulmonary metastasis ,busulfan ,neoplasms ,pulmonary metastasis ,RC254-282 ,Chemotherapy ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Retrospective cohort study ,medicine.disease ,Primary tumor ,melphalan ,030104 developmental biology ,Metastatic Ewing Sarcoma ,030220 oncology & carcinogenesis ,lung irradiation ,oncology ,Sarcoma ,business ,medicine.drug - Abstract
Purpose: To analyze toxicity and outcome predictors in Ewing sarcoma patients with lung metastases treated with busulfan and melphalan (BU-MEL) followed by whole-lung irradiation (WLI). Methods: This retrospective study included 68 lung metastatic Ewing Sarcoma patients who underwent WLI after BU-MEL with autologous stem cell transplantation, as part of two prospective and consecutive treatment protocols. WLI 12 Gy for <, 14 years old and 15 Gy for ≥14 years old patients were applied at least eight weeks after BU-MEL. Toxicity, overall survival (OS), event-free survival (EFS) and pulmonary relapse-free survival (PRFS) were estimated and analyzed. Results: After WLI, grade 1–2 and grade 3 clinical toxicity was reported in 16.2% and 5.9% patients, respectively. The five-year OS, EFS and PRFS with 95% confidence interval (CI) were 69.8% (57.1–79.3), 61.2% (48.4–71.7) and 70.5% (56.3–80.8), respectively. Patients with good histological necrosis of the primary tumor after neoadjuvant chemotherapy showed a significant decreased risk of pulmonary relapse or death compared to patients with poor histological necrosis. Conclusions: WLI at recommended doses and time interval after BU-MEL is feasible and might contribute to the disease control in Ewing sarcoma with lung metastases and responsive disease. Further studies are needed to explore the treatment stratification based on the histological response of the primary tumor.
- Published
- 2021
9. Isolated Forehead Swelling
- Author
-
Valentina Kiren, Alessia Saccari, Egidio Barbi, Luisa Cortellazzo Wiel, Irene Berti, Lorenzo Calligaris, Marco Rabusin, Daniela Nisticò, Nistico, D., Cortellazzo Wiel, L., Berti, I., Calligaris, L., Rabusin, M., Saccari, A., Barbi, E., and Kiren, V.
- Subjects
medicine.medical_specialty ,business.industry ,acute lymphocytic leukemia ,acute myeloid leukemia ,extramedullary acute myeloid leukemia tumor ,granulocytic sarcoma ,leukemia cutis ,myeloid sarcoma ,Leukemia cutis ,medicine.disease ,Dermatology ,medicine.anatomical_structure ,Acute lymphocytic leukemia ,Pediatrics, Perinatology and Child Health ,leukemia cuti ,medicine ,Forehead ,Myeloid sarcoma ,medicine.symptom ,Swelling ,business - Abstract
N/A
- Published
- 2021
10. The Challenge of Next Generation Sequencing in a Boy With Severe Mononucleosis and EBV-related Lymphoma
- Author
-
Nagua Giurici, Annalisa Marcuzzi, Alberto Tommasini, Flavio Faletra, Federico Verzegnassi, Diego Vozzi, Valentina Kiren, Anna Monica Bianco, Erica Valencic, Verzegnassi, F., Valencic, E., Kiren, V., Giurici, N., Bianco, A. M., Marcuzzi, A., Vozzi, D., Tommasini, A., and Faletra, F.
- Subjects
0301 basic medicine ,Male ,Herpesvirus 4, Human ,Mononucleosis ,Adolescent ,Lymphoma ,Infectious Mononucleosi ,medicine.disease_cause ,NO ,whole exome sequencing ,CTPS2 ,03 medical and health sciences ,0302 clinical medicine ,Epstein Barr virus ,hemophagocytic lymphohistiocytosis ,lymphoma ,Humans ,Exome ,High-Throughput Nucleotide Sequencing ,Infectious Mononucleosis ,Mutation ,hemophagocytic lymphohistiocytosi ,medicine ,Exome sequencing ,Hemophagocytic lymphohistiocytosis ,business.industry ,Herpesvirus 4 ,Hematology ,medicine.disease ,Penetrance ,Epstein–Barr virus ,030104 developmental biology ,Oncology ,Epstein Barr viru ,Pediatrics, Perinatology and Child Health ,Immunology ,Primary immunodeficiency ,business ,030215 immunology ,Human - Abstract
A severe course of infectious mononucleosis should always lead up to the suspicion of a primary immunodeficiency. We describe the case of a boy with severe mononucleosis accompanied by the development of hemophagocytic lymphohistiocytosis and lymphoma. By whole exome sequencing, we identified a mutation of uncertain significance in CTPS2, a gene closely related to CTPS1, which is involved in a primary immune deficiency with susceptibility to herpesviruses. We discuss the challenge of a correct interpretation of data from whole exome sequencing, questioning whether the CTPS2 variant found in our patient is just an incidental finding or a mutation with variable penetrance.
- Published
- 2017
11. A Singular Case of Congenital Self-healing Histiocytosis with Skin, Liver and Atypical Eye Involvement
- Author
-
Giovanna Ventura, Valentina Kiren, Chiara Bibalo, Loredana Lepore, Fulvio Parentin, Stefano Pensiero, and Serena Pastore
- Subjects
Intraocular pressure ,Pathology ,medicine.medical_specialty ,genetic structures ,Forceps ,Glaucoma ,Trabeculectomy ,Skin Diseases ,Antigens, CD1 ,Langerhans cell histiocytosis ,Humans ,Immunology and Allergy ,Medicine ,Iridocorneal Endothelial Syndrome ,Iris (anatomy) ,Intraocular Pressure ,Histiocyte ,Ultrasonography ,business.industry ,Liver Diseases ,S100 Proteins ,Infant ,Convalescence ,medicine.disease ,Trabeculotomy ,eye diseases ,Histiocytosis, Langerhans-Cell ,Ophthalmology ,Histiocytosis ,medicine.anatomical_structure ,Female ,business - Abstract
To describe a rare case of congenital self-healing Langerhans cell histiocytosis (CSHLCH) presenting with atypical eye involvement.Case report.A female newborn presented with purpuric lesions over the trunk, limbs, and face. Liver ultrasonography revealed hypoechogenic lesions with blurred borders. Biomicroscopy showed right posterior synechiae with fibrinoid deposits on the lens. At 7 months she presented with right acute glaucoma.Biomicroscopy showed the presence of inflammatory pseudo-membrane covering the anterior surface of the lens, iris, and iridocorneal angle. Ab externo trabeculotomy was performed; access to the anterior chamber with capsulorrhexis forceps permitted a peeling of the pseudo-membrane with normalization of the intraocular pressure. Histologic examination of the membrane revealed an inflammatory tissue with CD1a and S-100 positive histiocytic cells.This is the first case of CSHLCH describing acute glaucoma secondary to a pseudo-inflammatory membrane with typical histiocytic cells, occluding the iridocorneal angle.
- Published
- 2011
- Full Text
- View/download PDF
12. Experience from a single paediatric transplant centre with identification of some protective and risk factors concerning the development of hepatic veno-occlusive disease in children after allogeneic hematopoietic stem cell transplant
- Author
-
Massimo Gregori, Antonio Pizzol, Valentina Kiren, Paolo Tamaro, Giovanna Ferrara, Marta Minute, Marcella Montico, Natalia Maximova, Maximova, N, Ferrara, G, Minute, M, Pizzol, A, Kiren, V, Montico, M, Gregori, M, and Tamaro, Paolo
- Subjects
hepatic veno-occlusive disease ,allogeneic hematopoietic stem cell transplant ,Male ,medicine.medical_specialty ,Hepatic veno-occlusive disease ,Adolescent ,medicine.medical_treatment ,Population ,Hepatic Veno-Occlusive Disease ,Hematopoietic stem cell transplantation ,Disease ,Defibrotide ,Sepsis ,Young Adult ,Risk Factors ,Internal medicine ,medicine ,Humans ,Transplantation, Homologous ,Mortality ,education ,Child ,Retrospective Studies ,education.field_of_study ,business.industry ,Mortality rate ,Hematopoietic Stem Cell Transplantation ,Infant, Newborn ,Infant ,Hematology ,medicine.disease ,Tacrolimus ,Surgery ,surgical procedures, operative ,Child, Preschool ,Female ,business ,medicine.drug - Abstract
Hepatic veno-occlusive disease (VOD) is a frequent and severe complication of hematopoietic stem cell transplantation (HSCT) affecting 9.6–17.3 % of cases. 200 HSCT, performed between January 1995 and March 2013 in our Paediatric HSCT Centre in Trieste, were retrospectively analysed to evaluate the frequency of VOD and to identify the associated risk factors. The frequency of VOD according to the Seattle criteria was 17 %, within the range reported in literature. The mortality rate was 37.5 % (75 out of 200 transplantations) in the general population and 73.5 % (25 out of 34) in VOD patients (p
- Published
- 2014
13. First description of Merkel Cell polyomavirus DNA detection in a patient with Stevens-Johnson syndrome
- Author
-
Marilena Granzotto, Natalia Maximova, Davide Zanon, Valentina Kiren, Manola Comar, Maximova, N, Granzotto, M, Kiren, V, Zanon, D, and Comar, Manola
- Subjects
Pathology ,medicine.medical_specialty ,Mucocutaneous zone ,Merkel cell polyomavirus ,Biology ,DNA sequencing ,chemistry.chemical_compound ,Young Adult ,Virology ,medicine ,Cluster Analysis ,Humans ,Young adult ,Phylogeny ,Skin ,Merkel cell carcinoma ,Sequence Analysis, DNA ,Amplicon ,Viral Load ,biology.organism_classification ,medicine.disease ,Infectious Diseases ,Blood ,chemistry ,Italy ,Stevens-Johnson Syndrome ,DNA, Viral ,Female ,Viral load ,merkel cell virus ,Cidofovir - Abstract
Merkel Cell polyomavirus (MCPyV), a ubiquitous DNA tumor virus, has been found to be associated with Merkel cell carcinoma and chronic lymphocytic leukaemia while other associations are still being explored. MCPyV sequences have also been detected in normal tissues of tumor patients and in the blood of healthy donors. This report documents a new MCPyV association with the Stevens–Johnson syndrome, a rare immune-modulated mucocutaneous process particularly associated with specific drugs and infective agents. A high MCPyV viral load was detected simultaneously in fluid from skin lesions (2.0 × 104 copies/ml) and in matched blood (7.4 × 105 copies/ml) from a young adult patient after bone marrow transplant for a relapsed T-cell acute lymphatic leukaemia. MCPyV clearance concurred with the complete resolution of skin lesions after 5 days of cidofovir treatment. DNA sequencing classified the amplicons as the European/Italian MKL-1 strain. Given its ubiquitous nature, MCPyV could account for part of Stevens–Johnson syndrome idiopathic cases. J. Med. Virol. 85:918–923, 2013. © 2013 Wiley Periodicals, Inc.
- Published
- 2013
14. Uselessness of anti-actin antibody in celiac disease screening
- Author
-
S Quaglia, Tarcisio Not, Alessandro Ventura, Valentina Kiren, Elisa Fabbro, Fortunato Ferrara, Laura Rubert, Fabbro, E, Rubert, L, Quaglia, S, Ferrara, F, Kiren, V, Ventura, Alessandro, and Not, Tarcisio
- Subjects
Adult ,Male ,Pathology ,medicine.medical_specialty ,Phage display ,Adolescent ,Clinical Biochemistry ,Enzyme-Linked Immunosorbent Assay ,macromolecular substances ,Biology ,Immunofluorescence ,environment and public health ,Biochemistry ,Sensitivity and Specificity ,Disease Screening ,Cell Line, Tumor ,medicine ,Humans ,In patient ,cardiovascular diseases ,Child ,Fluorescent Antibody Technique, Indirect ,Autoantibodies ,Anti-actin antibody ,medicine.diagnostic_test ,Biochemistry (medical) ,Autoantibody ,General Medicine ,Actins ,enzymes and coenzymes (carbohydrates) ,Celiac Disease ,Child, Preschool ,Anti-transglutaminase antibodies ,cardiovascular system ,biology.protein ,Female ,Antibody - Abstract
Background Serum anti-actin IgA antibodies (AAA) were identified in patients with celiac disease (CD), and a close correlation emerged between the presence of AAA and mucosa damage, but test for AAA found in celiacs have a wide range of sensitivity and specificity values. Aim To compare 1) the sensitivity and specificity of untreated, calcium-chelated and heated sera from 102 celiacs, 52 sick patients and 103 healthy controls in the determination of AAA, and 2) the reliability of AAA with anti-transglutaminase antibodies (anti-tTG) in diagnosing celiac disease and in predicting intestinal damage. The intestinal derived AAA was isolated by using the phage-display library technique. Results Treated sera was significantly more sensitive than untreated (p = 0.0001), and showed a significant correlation between AAA and the three degrees (3a, 3b, 3c) of intestinal damage (p = 0.01). Sensitivity and specificity values of anti-tTG assay were higher than the AAA assay, and anti-tTG serum-concentration was only significantly correlated with more severe (3b and 3c) intestinal damage degrees. AAA isolated by phage display showed similar results of serum AAA in immunofluorescence assay. Conclusions Notwithstanding correlation between AAA and celiac disease, AAA assay, also after treatments, has little to offer in screening for CD compared to the well-established anti-transglutaminase assay.
- Published
- 2008
15. Mass screening for coeliac disease using antihuman transglutaminase antibody assay
- Author
-
Valentina Kiren, A. Lenhardt, Chiara Trevisiol, V. Baldas, Tarcisio Not, Daniele Sblattero, Alberto Tommasini, Elena Neri, Daniela Santon, Giuliano Torre, S. Martellossi, Irene Berti, Andrew Bradbury, Giorgio Tamburlini, E. Zamuner, Roberto Marzari, Andrea Spanò, Tania Gerarduzzi, Sergio Crovella, Irene Bruno, Alessandro Ventura, Tommasini, A, Not, Tarcisio, Kiren, V, Baldas, V, Santon, D, Trevisiol, C, Berti, I, Neri, E, Gerarduzzi, T, Bruno, I, Lenhardt, A, Zamuner, E, Spano, A, Crovella, Sergio, Martellossi, S, Torre, G, Sblattero, Daniele, Marzari, Roberto, Bradbury, A, Tamburlini, G, and Ventura, Alessandro
- Subjects
Male ,medicine.medical_specialty ,Atoms ,Cross-sectional study ,Antibodie ,Population ,Enzyme-Linked Immunosorbent Assay ,Asymptomatic ,Coeliac disease ,Antibodies ,Follow-Up Studie ,Predictive Value of Tests ,Internal medicine ,Immunopathology ,Biopsy ,medicine ,Humans ,Mass Screening ,Prospective Studies ,Prospective cohort study ,education ,Child ,Mass screening ,Cross-Sectional Studie ,education.field_of_study ,Transglutaminases ,medicine.diagnostic_test ,business.industry ,Celiac Disease ,Cross-Sectional Studies ,Female ,Follow-Up Studies ,Immunoglobulin A ,Immunoglobulin G ,Italy ,Patient Compliance ,nutritional and metabolic diseases ,Celiac disease Transglutaminase ,medicine.disease ,Prospective Studie ,Pediatrics, Perinatology and Child Health ,Immunology ,Commentary ,Original Article ,medicine.symptom ,business ,Human - Abstract
Aims: To determine coeliac disease prevalence by an anti-transglutaminase antibody assay in a large paediatric population; to evaluate acceptance of the screening programme, dietary compliance, and long term health effects. Methods: Cross-sectional survey of 3188 schoolchildren (aged 6–12) and prospective follow up of diagnosed cases. Main outcome measures were: prevalence of coeliac disease defined by intestinal biopsy or positivity to both human tissue transglutaminase and anti-endomysium antibodies in HLA DQ2-8 positive subjects; percentage of children whose families accepted screening; dietary compliance as defined by negativity for anti-transglutaminase antibodies; and presence of clinical or laboratory abnormalities at 24 month follow up. Results: The families of 3188/3665 children gave their consent (87%). Thirty biopsy proven coeliacs were identified (prevalence 1:106). Three other children testing positive for both coeliac related autoantibodies and HLA DQ2-8 but refusing biopsy were considered as having coeliac disease (prevalence 1:96). Of 33 cases, 12 had coeliac related symptoms. The 30 biopsy proven coeliacs followed a gluten-free diet. Of 28 subjects completing 18–24 months follow up, 20 (71.4%) were negative for anti-transglutaminase antibodies, while eight were slightly positive; symptoms resolved in all 12 symptomatic children. Conclusions: Prevalence of coeliac disease is high in Italian schoolchildren. Two thirds of cases were asymptomatic. Acceptance of the programme was good, as was dietary compliance. Given the high prevalence and possible complications of untreated coeliac disease, the availability of a valid screening method, and evidence of willingness to comply with dietary treatment population mass screening deserves careful consideration.
- Published
- 2004
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.